Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
High-dose Wegovy leads to substantial weight loss in trial
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,
Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial
Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss achieved by regular semaglutide in a late-stage trial.
Ozempic, Wegovy face US Medicare price negotiations
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Former Trump health official: Medicare should cover Wegovy — but not negotiate its price
Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 weight-loss drugs — but says subjecting Wegovy to price controls is a bad move.
Medicare drug price negotiations to target Ozempic, Wegovy and other drugs
The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.
6d
on MSN
Zealand Seeks to Usurp Wegovy, Zepbound With New Obesity Drug
There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...
The Financial Express
8h
Weight loss pills Ozempic, Wegovy and Trizepatide enter Indian market
Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...
3d
Gov. Hochul wants to lower cost of anti-obesity drugs, expand access to Medicaid recipients
The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...
1d
on MSN
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
1d
on MSN
Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiations
The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of ...
3d
Obesity label is medically flawed, says global report
Calling people obese is medically "flawed" - and the definition should be split into two, a report from global experts says.
The Economist
3d
Is obesity a disease?
By coincidence (they started before GLP -1 drugs were approved for slimming), a group of 56 doctors have just answered that ...
4d
on MSN
Experts Argue It’s Time for Obesity to Be Defined Beyond BMI
A crude measure of weight relative to height, BMI is commonly used to diagnose obesity—even though many experts and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback